NO324357B1 - Anvendelse av et ostroprogestagenhormonpreparat ved fremstillingen av et medikament for behandling av ostrogenforstyrrelser og osteoporose hos postmenopausale kvinner, samt anvendelse av et farmasoytisk preparat ved fremstilling av et medikament for a stoppe ovulasjon - Google Patents
Anvendelse av et ostroprogestagenhormonpreparat ved fremstillingen av et medikament for behandling av ostrogenforstyrrelser og osteoporose hos postmenopausale kvinner, samt anvendelse av et farmasoytisk preparat ved fremstilling av et medikament for a stoppe ovulasjon Download PDFInfo
- Publication number
- NO324357B1 NO324357B1 NO19991593A NO991593A NO324357B1 NO 324357 B1 NO324357 B1 NO 324357B1 NO 19991593 A NO19991593 A NO 19991593A NO 991593 A NO991593 A NO 991593A NO 324357 B1 NO324357 B1 NO 324357B1
- Authority
- NO
- Norway
- Prior art keywords
- estradiol
- use according
- treatment
- pharmaceutical preparation
- manufacture
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 43
- 229940011871 estrogen Drugs 0.000 title claims description 23
- 239000000262 estrogen Substances 0.000 title claims description 23
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 title claims description 16
- 238000004519 manufacturing process Methods 0.000 title claims description 13
- 229940088597 hormone Drugs 0.000 title claims description 11
- 239000005556 hormone Substances 0.000 title claims description 11
- 239000003814 drug Substances 0.000 title claims description 10
- 230000016087 ovulation Effects 0.000 title claims description 10
- 208000001132 Osteoporosis Diseases 0.000 title claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 7
- 208000035475 disorder Diseases 0.000 title claims description 6
- 229960005309 estradiol Drugs 0.000 claims description 37
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 34
- 229930182833 estradiol Natural products 0.000 claims description 34
- 229960004190 nomegestrol acetate Drugs 0.000 claims description 28
- IIVBFTNIGYRNQY-YQLZSBIMSA-N nomegestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 IIVBFTNIGYRNQY-YQLZSBIMSA-N 0.000 claims description 28
- 229940035811 conjugated estrogen Drugs 0.000 claims description 14
- 241000283086 Equidae Species 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 6
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 claims description 5
- 229960004766 estradiol valerate Drugs 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims 6
- 230000000737 periodic effect Effects 0.000 claims 1
- 230000009245 menopause Effects 0.000 description 20
- 239000003826 tablet Substances 0.000 description 13
- 239000000583 progesterone congener Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 10
- 201000000736 Amenorrhea Diseases 0.000 description 8
- 206010001928 Amenorrhoea Diseases 0.000 description 8
- 231100000540 amenorrhea Toxicity 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000007906 compression Methods 0.000 description 7
- 230000006835 compression Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 230000002357 endometrial effect Effects 0.000 description 6
- 238000002657 hormone replacement therapy Methods 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 description 4
- 239000003082 abrasive agent Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 230000001076 estrogenic effect Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000007907 direct compression Methods 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000006828 endometrial hyperplasia Diseases 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960004911 nomegestrol Drugs 0.000 description 2
- KZUIYQJTUIACIG-YBZCJVABSA-N nomegestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 KZUIYQJTUIACIG-YBZCJVABSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- -1 progestagen compound Chemical class 0.000 description 2
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 2
- 235000012752 quinoline yellow Nutrition 0.000 description 2
- 239000004172 quinoline yellow Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- NVUUMOOKVFONOM-GPBSYSOESA-N 19-Norprogesterone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 NVUUMOOKVFONOM-GPBSYSOESA-N 0.000 description 1
- 150000000318 19-norprogesterones Chemical class 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003439 Artificial menopause Diseases 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010085330 Estradiol Receptors Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 229920003071 Polyclar® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229960004913 dydrogesterone Drugs 0.000 description 1
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 1
- 229940060626 estradiol valerate 2 mg Drugs 0.000 description 1
- 150000002159 estradiols Chemical class 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229960001207 micronized progesterone Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000000757 progestagenic effect Effects 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 1
- 229940051201 quinoline yellow Drugs 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/811—Drug, bio-affecting and body treating compositions involving sex selection or contraception
Description
Claims (19)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9612239A FR2754179B1 (fr) | 1996-10-08 | 1996-10-08 | Nouvelle composition hormononale et son utilisation |
PCT/FR1997/001792 WO1998015279A1 (fr) | 1996-10-08 | 1997-10-08 | Composition hormonale constituee d'un compose estrogene et d'un compose progestatif |
Publications (3)
Publication Number | Publication Date |
---|---|
NO991593D0 NO991593D0 (no) | 1999-03-31 |
NO991593L NO991593L (no) | 1999-06-07 |
NO324357B1 true NO324357B1 (no) | 2007-10-01 |
Family
ID=9496456
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19991593A NO324357B1 (no) | 1996-10-08 | 1999-03-31 | Anvendelse av et ostroprogestagenhormonpreparat ved fremstillingen av et medikament for behandling av ostrogenforstyrrelser og osteoporose hos postmenopausale kvinner, samt anvendelse av et farmasoytisk preparat ved fremstilling av et medikament for a stoppe ovulasjon |
NO2012002C NO2012002I2 (no) | 1996-10-08 | 2012-01-24 | Nomegestrolacetat + fritt eller esterifisert østradiol |
NO2017043C NO2017043I2 (no) | 1996-10-08 | 2017-08-08 | Nomegestrolacetat + fritt eller esterifisert østradiol - forlenget SPC |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2012002C NO2012002I2 (no) | 1996-10-08 | 2012-01-24 | Nomegestrolacetat + fritt eller esterifisert østradiol |
NO2017043C NO2017043I2 (no) | 1996-10-08 | 2017-08-08 | Nomegestrolacetat + fritt eller esterifisert østradiol - forlenget SPC |
Country Status (38)
Country | Link |
---|---|
US (4) | US6831073B1 (no) |
EP (2) | EP0956022B1 (no) |
JP (1) | JP4883542B2 (no) |
KR (2) | KR20000048981A (no) |
CN (3) | CN101229173A (no) |
AP (1) | AP1171A (no) |
AR (2) | AR009113A1 (no) |
AT (2) | ATE353652T1 (no) |
AU (1) | AU745571B2 (no) |
BR (1) | BR9712274A (no) |
CA (1) | CA2268358C (no) |
CL (1) | CL2011000017A1 (no) |
CZ (1) | CZ298402B6 (no) |
DE (3) | DE69721314T2 (no) |
DK (2) | DK0956022T3 (no) |
DZ (1) | DZ2327A1 (no) |
ES (2) | ES2198006T3 (no) |
FR (2) | FR2754179B1 (no) |
HK (1) | HK1210708A1 (no) |
HU (2) | HU227450B1 (no) |
ID (1) | ID21569A (no) |
IL (1) | IL129194A (no) |
LU (1) | LU91932I2 (no) |
MA (1) | MA24370A1 (no) |
MY (1) | MY128482A (no) |
NO (3) | NO324357B1 (no) |
NZ (1) | NZ334876A (no) |
OA (1) | OA11033A (no) |
PL (1) | PL192979B1 (no) |
PT (2) | PT1334725E (no) |
RU (1) | RU2274450C2 (no) |
SK (2) | SK285056B6 (no) |
TN (1) | TNSN97164A1 (no) |
TR (1) | TR199900764T2 (no) |
TW (1) | TW491704B (no) |
WO (1) | WO1998015279A1 (no) |
YU (1) | YU18099A (no) |
ZA (1) | ZA979011B (no) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO330885B1 (no) * | 1999-10-25 | 2011-08-08 | Laboratopire Theramax | Anvendelse av et preparat som omfatter østradiol og nomegestrolacetat for fremstilling av et prevensjonsprodukt, samt et prevensjonsprodukt. |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4344462C2 (de) | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
DE19549264A1 (de) * | 1995-12-23 | 1997-06-26 | Schering Ag | Verfahren und Kit zur Kontrazeption |
FR2754179B1 (fr) | 1996-10-08 | 1998-12-24 | Theramex | Nouvelle composition hormononale et son utilisation |
WO2001030356A1 (fr) * | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation |
FR2814074B1 (fr) * | 2000-09-15 | 2003-03-07 | Theramex | Nouvelles compositions estro-progestatives topiques a effet systemique |
FR2823976A1 (fr) * | 2001-04-25 | 2002-10-31 | Theramex | Nouvelle composition hormonale et son utilisation |
GT200500315A (es) * | 2004-11-02 | 2006-06-06 | Formas de dosificacion oral solidas que contienen una dosis baja de estradiol | |
AR065816A1 (es) * | 2007-03-26 | 2009-07-01 | Theramex | Regimen anticonceptivo oral |
US20080293683A1 (en) * | 2007-05-24 | 2008-11-27 | University Of Kansas Medical Center | Hormone Replacement Therapy |
AR066166A1 (es) * | 2007-09-21 | 2009-07-29 | Organon Nv | Sistema de suministro de droga |
WO2015086489A1 (en) | 2013-12-11 | 2015-06-18 | Merck Sharp & Dohme B.V. | Drug delivery system for delivery of anti-virals |
US10413504B2 (en) | 2013-12-11 | 2019-09-17 | Merck Sharp & Dohme Corp. | Intravaginal ring drug delivery system |
KR20240005348A (ko) | 2022-07-05 | 2024-01-12 | 신규식 | 소멸특허 관리 및 특허거래 시스템 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3271392A (en) * | 1965-09-14 | 1966-09-06 | American Home Prod | 17alpha-[3'-furyl]-estrogens |
US4390531A (en) | 1981-08-10 | 1983-06-28 | Syntex Pharmaceuticals International Ltd. | Method of contraception using peak progestogen dosage |
US4921843A (en) | 1988-10-20 | 1990-05-01 | Pasquale Samuel A | Contraception system and method |
US4826831A (en) * | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
US4628051A (en) * | 1983-09-26 | 1986-12-09 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
JPS61243059A (ja) * | 1985-04-19 | 1986-10-29 | Konishi Kagaku Kogyo Kk | 高純度4,4′−ジヒドロキシジフエニルスルホンの製造法 |
ZA87332B (en) | 1986-02-27 | 1987-08-26 | Warner Lambert Co | Compositions containing fixed combinations |
US5208225A (en) * | 1986-02-27 | 1993-05-04 | Warner-Lambert Company | Compositions containing fixed combinations |
DK174724B1 (da) | 1986-07-15 | 2003-10-06 | Wyeth Corp | Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet |
CA1332227C (en) | 1987-09-24 | 1994-10-04 | Robert F. Casper | Oral contraceptive formulation |
US5108995A (en) * | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
US5256421A (en) * | 1987-09-24 | 1993-10-26 | Jencap Research Ltd. | Hormone preparation and method |
DK174071B1 (da) * | 1987-09-24 | 2002-05-21 | Jencap Res Ltd | Kontraceptivt præparat i form af en pakning omfattende enhedsdoser |
US5276022A (en) * | 1987-09-24 | 1994-01-04 | Jencap Research Ltd. | Hormone preparation and method |
HUT52382A (en) | 1988-03-14 | 1990-07-28 | Sandoz Ag | Process for producing pharmaceutical compositions comprising as active ingredient unsubstituted progestin in 19-position and estrogen in the given case |
IE71203B1 (en) | 1990-12-13 | 1997-02-12 | Akzo Nv | Low estrogen oral contraceptives |
IE62665B1 (en) | 1990-12-17 | 1995-02-22 | Akzo Nv | Contraceptive regimen |
FR2695826B1 (fr) * | 1992-09-21 | 1995-01-06 | Theramex | Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention. |
US6150343A (en) | 1993-06-30 | 2000-11-21 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
US5554601A (en) * | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
US5552394A (en) * | 1994-07-22 | 1996-09-03 | The Medical College Of Hampton Roads | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
US6613757B1 (en) | 1994-09-22 | 2003-09-02 | Board Of Regents, The University Of Texas System | Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy |
SE9403389D0 (sv) | 1994-10-06 | 1994-10-06 | Astra Ab | Pharmaceutical composition containing derivattves of sex hormones |
FR2737411B1 (fr) * | 1995-08-01 | 1997-10-17 | Theramex | Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques |
DE19540253C2 (de) | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
DE19549264A1 (de) * | 1995-12-23 | 1997-06-26 | Schering Ag | Verfahren und Kit zur Kontrazeption |
WO1997041868A1 (en) | 1996-05-08 | 1997-11-13 | American Home Products Corporation | Oral contraceptive |
WO1997041869A1 (en) | 1996-05-08 | 1997-11-13 | American Home Products Corporation | Oral contraceptive |
WO1997041872A1 (en) | 1996-05-08 | 1997-11-13 | American Home Products Corporation | Oral contraceptive |
WO1997041871A1 (en) | 1996-05-08 | 1997-11-13 | American Home Products Corporation | Oral contraceptive |
AU2926897A (en) | 1996-05-08 | 1997-11-26 | American Home Products Corporation | Oral contraceptive |
US5888543A (en) * | 1996-07-26 | 1999-03-30 | American Home Products Corporation | Oral contraceptives |
WO1998004267A1 (en) | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Progestin/estrogen oral contraceptive |
AU3888597A (en) | 1996-07-26 | 1998-02-20 | American Home Products Corporation | Oral contraceptive |
IL127923A (en) | 1996-07-26 | 2004-07-25 | Wyeth Corp | Pharmaceutical preparation swallowed to prevent pregnancy |
AU3961697A (en) | 1996-07-26 | 1998-02-20 | American Home Products Corporation | Oral contraceptive |
EP0921804B1 (en) | 1996-07-26 | 2003-09-10 | Wyeth | Biphasic oral contraceptive method and kit comprising a combination of a progestin and estrogen |
FR2754179B1 (fr) * | 1996-10-08 | 1998-12-24 | Theramex | Nouvelle composition hormononale et son utilisation |
WO2001030355A1 (fr) | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation |
DE19705229C2 (de) | 1997-02-12 | 1999-04-15 | Hesch Rolf Dieter Prof Dr Med | Verwendung von drei Hormonkomponenten zur hormonalen Kontrazeption zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
US5898032A (en) | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
AU9028098A (en) | 1997-08-27 | 1999-03-16 | Ortho Pharmaceutical Corporation | Combinations of endometrial sparing progestins and endometrial atrophizing progestins with estrogens, in oral contraception |
DE19739916C2 (de) * | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
AU759925B2 (en) | 1997-09-12 | 2003-05-01 | Wyeth | Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin |
WO2001030356A1 (fr) | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation |
-
1996
- 1996-10-08 FR FR9612239A patent/FR2754179B1/fr not_active Expired - Fee Related
-
1997
- 1997-10-07 TN TNTNSN97164A patent/TNSN97164A1/fr unknown
- 1997-10-08 DZ DZ970177A patent/DZ2327A1/xx active
- 1997-10-08 DE DE69721314T patent/DE69721314T2/de not_active Expired - Lifetime
- 1997-10-08 YU YU18099A patent/YU18099A/sh unknown
- 1997-10-08 KR KR1019990703032A patent/KR20000048981A/ko not_active IP Right Cessation
- 1997-10-08 DE DE69737373T patent/DE69737373T2/de not_active Expired - Lifetime
- 1997-10-08 ES ES97944940T patent/ES2198006T3/es not_active Expired - Lifetime
- 1997-10-08 PT PT03008979T patent/PT1334725E/pt unknown
- 1997-10-08 MY MYPI97004717A patent/MY128482A/en unknown
- 1997-10-08 AU AU46273/97A patent/AU745571B2/en not_active Expired
- 1997-10-08 NZ NZ334876A patent/NZ334876A/xx not_active IP Right Cessation
- 1997-10-08 ZA ZA9709011A patent/ZA979011B/xx unknown
- 1997-10-08 DK DK97944940T patent/DK0956022T3/da active
- 1997-10-08 CZ CZ0112099A patent/CZ298402B6/cs not_active IP Right Cessation
- 1997-10-08 CN CNA2007101694575A patent/CN101229173A/zh active Pending
- 1997-10-08 IL IL12919497A patent/IL129194A/xx not_active IP Right Cessation
- 1997-10-08 MA MA24828A patent/MA24370A1/fr unknown
- 1997-10-08 EP EP97944940A patent/EP0956022B1/fr not_active Expired - Lifetime
- 1997-10-08 CN CN97180380A patent/CN1239893A/zh active Pending
- 1997-10-08 BR BR9712274-2A patent/BR9712274A/pt not_active Application Discontinuation
- 1997-10-08 SK SK438-99A patent/SK285056B6/sk not_active IP Right Cessation
- 1997-10-08 EP EP03008979A patent/EP1334725B1/fr not_active Expired - Lifetime
- 1997-10-08 CN CN201510024865.6A patent/CN104706641A/zh active Pending
- 1997-10-08 PT PT97944940T patent/PT956022E/pt unknown
- 1997-10-08 PL PL332610A patent/PL192979B1/pl unknown
- 1997-10-08 ES ES03008979T patent/ES2282539T3/es not_active Expired - Lifetime
- 1997-10-08 AR ARP970104638A patent/AR009113A1/es not_active Application Discontinuation
- 1997-10-08 WO PCT/FR1997/001792 patent/WO1998015279A1/fr active IP Right Grant
- 1997-10-08 TR TR1999/00764T patent/TR199900764T2/xx unknown
- 1997-10-08 AT AT03008979T patent/ATE353652T1/de active
- 1997-10-08 HU HU9904508A patent/HU227450B1/hu active Protection Beyond IP Right Term
- 1997-10-08 AP APAP/P/1999/001500A patent/AP1171A/en active
- 1997-10-08 CA CA2268358A patent/CA2268358C/fr not_active Expired - Lifetime
- 1997-10-08 KR KR1020067013702A patent/KR100782638B1/ko not_active IP Right Cessation
- 1997-10-08 ID IDW990211A patent/ID21569A/id unknown
- 1997-10-08 RU RU2003107072/15A patent/RU2274450C2/ru active
- 1997-10-08 JP JP51726398A patent/JP4883542B2/ja not_active Expired - Lifetime
- 1997-10-08 DK DK03008979T patent/DK1334725T3/da active
- 1997-10-08 US US09/284,147 patent/US6831073B1/en not_active Expired - Lifetime
- 1997-10-08 AT AT97944940T patent/ATE238057T1/de active
- 1997-10-08 SK SK5098-2005A patent/SK285455B6/sk active Protection Beyond IP Right Term
- 1997-10-15 TW TW086115281A patent/TW491704B/zh not_active IP Right Cessation
-
1999
- 1999-03-31 NO NO19991593A patent/NO324357B1/no not_active IP Right Cessation
- 1999-04-08 OA OA9900078A patent/OA11033A/fr unknown
- 1999-10-25 US US09/423,108 patent/US6906049B1/en not_active Expired - Lifetime
-
2004
- 2004-01-08 US US10/753,073 patent/US20040220163A1/en not_active Abandoned
-
2007
- 2007-01-03 US US11/649,672 patent/US7749987B2/en not_active Expired - Fee Related
-
2009
- 2009-10-26 AR ARP090104109A patent/AR073972A2/es not_active Application Discontinuation
-
2011
- 2011-01-06 CL CL2011000017A patent/CL2011000017A1/es unknown
-
2012
- 2012-01-13 LU LU91932C patent/LU91932I2/fr unknown
- 2012-01-19 FR FR12C0005C patent/FR12C0005I2/fr active Active
- 2012-01-23 DE DE201212000010 patent/DE122012000010I1/de active Pending
- 2012-01-24 NO NO2012002C patent/NO2012002I2/no not_active IP Right Cessation
- 2012-01-26 HU HUS1200002C patent/HUS1200002I1/hu unknown
-
2015
- 2015-11-24 HK HK15111561.9A patent/HK1210708A1/xx unknown
-
2017
- 2017-08-08 NO NO2017043C patent/NO2017043I2/no unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO330885B1 (no) * | 1999-10-25 | 2011-08-08 | Laboratopire Theramax | Anvendelse av et preparat som omfatter østradiol og nomegestrolacetat for fremstilling av et prevensjonsprodukt, samt et prevensjonsprodukt. |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7749987B2 (en) | Contraception method | |
US9084796B2 (en) | Hormonal composition and its use | |
US20110008409A1 (en) | Pharmaceutical preparation containing a gestagen, and kit and method for treating endometriosis using the preparation | |
KR100370908B1 (ko) | 기능부전성자궁출혈치료용약제의제조에유용한프로게스테론길항제 | |
JPH10513152A (ja) | 抗黄体ホルモンおよびプロゲスチンを含有する周期相ホルモン養生法 | |
US5891867A (en) | Hormonal medicaments and their use for the correction of oestrogenic deficiencies | |
DK167897B1 (da) | Farmaceutisk middel indeholdende prostaglandin, antigestagen og glucocorticoid samt anvendelse af disse forbindelser til fremstilling af farmaceutiske midler | |
RU2258512C2 (ru) | Противозачаточное лекарственное средство на основе гестагена и эстрогена и способ его получения | |
EP2150257A2 (en) | Drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen | |
EP2059248A1 (de) | Pharmazeutische zubereitung zur verminderung der endometriose | |
KR20030043797A (ko) | 호르몬 조성물 | |
WO2023152682A1 (en) | Contraceptive methods with scheduled bleeding effects | |
MXPA99003291A (en) | Hormonal composition consisting of an oestrogen compound and of a progestational compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: ZOELY - NOMEGESTROLACETAT/OESTRADIOL; NAT. REG. NO/DATE: (92) DATO FOR SAMME: 2011.07.27 20110727; FIRST REG. NO/DATE: (93) DATO FOR SAMME: 2011.07.27 20110727 Spc suppl protection certif: 2012002 Filing date: 20120124 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: ZOELY - NOMEGESTROLACETAT/OESTRADIOL; REG. NO/DATE: EU/1/11/690/001-002 20110727 Spc suppl protection certif: 2012002 Filing date: 20120124 Extension date: 20221008 |
|
SPCE | Application to extend a supplementary protection certificate (spc) |
Free format text: PRODUCT NAME: NOMEGESTROLACETAT + FRITT ELLER ESTERIFISERT OESTRADIOL; REG. NO/DATE: EU/1/11/690/001-002 20110727 Spc suppl protection certif: 2017043 Filing date: 20170808 |
|
MK1K | Patent expired | ||
SPCH | Extension of a supplementary protection certificate (spc) granted |
Free format text: PRODUCT NAME: NOMEGESTROLACETAT + FRITT ELLER ESTERIFISERT OESTRADIOL; REG. NO/DATE: EU/1/11/690/001-002 20110727 Spc suppl protection certif: 2017043 Filing date: 20170808 Extension date: 20230408 |
|
SPCS | Change of name or address of the owner of a supplementary protection certificate |
Owner name: THERAMEX HQ UK LIMITED, MC Spc suppl protection certif: 2017043 Owner name: THERAMEX HQ UK LIMITED, MC Spc suppl protection certif: 2012002 |
|
SPCX | Expiry of an spc |
Spc suppl protection certif: 2017043 Expiry date: 20230504 |